April McClain Delaney
April McClain Delaney (D-MD) bought $1K-$15K of $BRO (Brown & Brown, Inc. Common Stock) on Nov 20, 2025, part of 5 transactions in this filing (3 buys, 2 sells).
HillSignal flagged 5 timing concerns on this filing — trades that line up closely with related legislative or contract activity.
Companies in this filing · 5
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Suspicious Timing Detected
5 flagsRep. April McClain Delaney bought $1,001-$15,000 in $LH on 2025-11-17, 28 days before HR6727, the "Repealing the IMD Exclusion Act," which removes federal Medicaid payment prohibitions for mental health and substance use disorder services.
Rep. April McClain Delaney bought $1,001-$15,000 in $LH on 2025-11-17, 31 days before HR6894, the "Increasing Access to Quality Cardiac Rehabilitation Care Act of 2025," which expands Medicare coverage for cardiac and pulmonary rehabilitation.
Rep. April McClain Delaney bought $1,001-$15,000 in $LH on 2025-11-17, 31 days before HR6897, the "Thyroid Disease CARE Act of 2025," which authorizes $30 million annually for five years for thyroid disease research.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $BRO | Brown & Brown, Inc. Common Stock | $1K-$15K | $79.25 | $67.78 | -14.5% | Nov 20, 2025 |
| BUY | $LH | Labcorp Holdings Inc. Common Stock | $1K-$15K | — | — | — | Nov 17, 2025 |
| BUY | $MKL | Markel Group Inc. Common Stock | $1K-$15K | $1,955.11 | — | — | Nov 3, 2025 |
| PARTIAL SELL | $EME | EMCOR Group, Inc. Common Stock | $1K-$15K | — | — | — | Nov 17, 2025 |
| PARTIAL SELL | $PWR | Quanta Services, Inc. Common Stock | $1K-$15K | — | $604.97 | — | Nov 17, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Medical Nutrition Therapy Act of 2026
The Medical Nutrition Therapy Act of 2026 structurally expands Medicare Part B to cover nutrition counseling for obesity, cancer, HIV/AIDS, and eating disorders — a direct benefit expansion for MA insurers Humana, UnitedHealth, Centene, and CVS Health, which can integrate these services to manage chronic disease costs. The bill is early-stage (referred to Senate Finance, 2 co-sponsors), but real market data shows the affected tickers have experienced 19-70% 30-day gains, reflecting broader sector momentum.
Repealing the IMD Exclusion Act
HR 6727 eliminates a 16-bed limit on Medicaid reimbursement for inpatient behavioral health, structurally expanding the addressable market for psychiatric hospitals by an estimated 15–30%. The bill is early-stage (referred to committee), so no price action has materialized in $UHS or $ACAD from this bill specifically. Current data shows $UHS at $168.57 (down 5.81% over 30 days) and $ACAD at $22.47 (up 2.32% over 7 days).
Thyroid Disease CARE Act of 2025
HR6897 (Thyroid Disease CARE Act) authorizes $30M/year for five years for thyroid disease research and improved diagnostics. The bill is in early stage — referred to House Energy and Commerce Committee on December 18, 2025. Real market data shows diagnostic stocks trending negative over the past 30 days, with Labcorp down 1.53% and Abbott down 11.85%. Any impact is procedural and speculative at this stage.
Increasing Access to Quality Cardiac Rehabilitation Care Act of 2025
HR 6894 is an early-stage, low-probability bill that expands Medicare cardiac and pulmonary rehab supervision to PAs, NPs, and CNSs. It authorizes zero funding and remains in committee. Marginal upside for healthcare staffing firm AMN (allied health demand) is possible but contingent on passage. Labcorp (LH) sees no structural impact. Current market prices: AMN $20.62, LH $262.99.
Veterans Community Care Scheduling Improvement Act
HR3482 is a procedural authorization bill requiring the VA to build an online scheduling system for community care appointments. It mandates an IT system change but includes no explicit funding, and it does not directly increase patient volume or reimbursement rates. The market impact on healthcare stocks ($DGX, $LH, $HCA, $UHS, $AMN) is negligible in the near term.
Access to Genetic Counselor Services Act of 2026
S.3607 expands Medicare Part B to cover genetic counseling as a new provider category effective Jan 1, 2027, directly increasing the addressable patient population for genetic testing. This is a structural positive for Labcorp ($LH) and Quest Diagnostics ($DGX) through higher test volume, and for AMN Healthcare ($AMN) through increased demand for scarce genetic counselors. The bill is at early legislative stage (referred to Finance Committee) with companion bill HR6280 in the House.
Emergency Medical Services Reimbursement for On-Scene and Support Act
HR7277 is an early-stage bill that would allow Medicare to reimburse ambulance services for on-scene treatment without transport. The bill has 8 cosponsors, no explicit funding authorization, and a long legislative path ahead. No direct near-term market impact on publicly traded companies is identifiable from this legislation alone.
Rural Health Care Facilities Revitalization Act
HR7514 is an early-stage bill with no funding authorized and no path to passage evident — 3 cosponsors, referred to committee on introduction date only. Real market data shows $GEHC down -15.58% over 30 days and $TDOC flat at +0.37%. The market is correctly not pricing in any impact from this bill. No actionable trade signal exists.
To amend title VII of the Public Health Service Act to strengthen the mental health workforce, and for other purposes.
HR7787 is an early-stage bill authorizing a mental health provider loan forgiveness program. It has been referred to committee with no companion bill, zero appropriations, and minimal legislative momentum. Market impact is negligible at this stage. Real market data shows AMN Healthcare at $20.65, up 12.6% over 30 days, and Centene at $53.22, up 62.55% over 30 days, driven by other factors unrelated to this procedural bill.
Expanded Telehealth Access Act
The Expanded Telehealth Access Act (S.3834) is an early-stage Senate bill that permanently adds audiologists, physical therapists, occupational therapists, speech-language pathologists, and assistants to Medicare telehealth eligibility. No funding is authorized. Market data shows mixed conviction: TDOC down 4.87% in the last 7 days to $5.47, while AMWL gained 3.06% to $6.06, indicating no material premium is priced in for this low-probability legislative event.
Other Filings by April McClain Delaney
Free — no credit card
Get the next Delaney trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.